Search

Displaying results 1151 - 1160 of 7687 in total
  1. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the prevention of angina.

  2. Target

    Glutamate receptor ionotropic, kainate 4

    go.drugbank.com/bio_entities/BE0000827
    TargetHumans

    Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel. Cannot form functional channels on its own (PubMed:8263508). Shows channel activity only in heteromeric assembly with GRIK1, GRIK2 and GRIK3 sub...

    Synonyms: KA1, Glutamate receptor KA-1
  3. Target

    Glutamate receptor ionotropic, kainate 5

    go.drugbank.com/bio_entities/BE0000828
    TargetHumans

    Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. Cannot form functional channels on its own and produces channel activity only in...

    Synonyms: KA2, Glutamate receptor KA-2
  4. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes. … [L44096] In April 2026, the FDA approved an expanded indication for teplizumab, lowering the eligible age range from 8 years and older down to 1 year and older for patients with Stage 2 T1D.[L56140]

  5. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.

  6. Drug

    Methyl nicotinate

    go.drugbank.com/drugs/DB13882
    Approved

    Methyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.

  7. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.

  8. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

  9. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.

    Products: Nu-trihexyphenidyl
  10. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … [L40548,L40553] On July 13, 2022, nuvaxovid was granted an emergency use authorization by the FDA for the prevention of COVID-19 in adults, which was expanded to include patients ≥12 years of age in August